METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Clinical trials for METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to boost immune attack on hard-to-treat cancers
Disease control OngoingThis early-phase study tests a new drug called NBTXR3, which is injected into tumors and activated by radiation. It is combined with an immunotherapy (anti-PD-1) to see if it can help the immune system fight advanced cancers better. About 145 adults with various advanced solid tu…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: Nanobiotix • Aim: Disease control
Last updated May 16, 2026 23:48 UTC
-
Could estrogen shrink Hard-to-Treat breast tumors?
Disease control OngoingThis study tests if a form of estrogen called estradiol can help people with a specific type of triple negative breast cancer that has spread. The cancer must have a protein called ER beta, which may make tumors grow slower when exposed to estrogen. The goal is to see if the trea…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 16, 2026 23:48 UTC
-
Virus injection takes on Hard-to-Treat breast cancer in early trial
Disease control OngoingThis early-phase study tests a new treatment for metastatic triple negative breast cancer, a type that has spread and is hard to treat. The therapy uses a specially designed virus injected directly into tumors to infect and break them down. The main goal is to find the safest dos…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 16, 2026 23:38 UTC
-
New drug combo shows promise in Tough-to-Treat breast cancer
Disease control OngoingThis study tests two drugs—eribulin (chemotherapy) and copanlisib (targeted therapy)—together in people with metastatic triple-negative breast cancer that has spread or cannot be removed. The goal is to find the safest dose and see if the combination works better than eribulin al…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced or inoperable solid tumors, including certain breast, lung, and pancreatic cancers. The goal is to see if the combo can shrink tumors or slow their growth by blocking enzymes that cancer …
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:04 UTC